FDA warning on Intercept’s Ocaliva after patient deaths

22nd September 2017 Uncategorised 0

US regulators have issued a safety communication warning of the risk for serious liver injury and death from incorrect dosing of Intercept Pharmaceuticals’ Ocaliva in patients with primary biliary cholangitis.

More: FDA warning on Intercept’s Ocaliva after patient deaths
Source: News